CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

• Published in: Clinical and translational radiation oncology 2020-11, Vol.25, p.61-66
• Main Authors: Walls, Gerard M., Oughton, Jamie B., Chalmers, Anthony J., Brown, Sarah, Collinson, Fiona, Forster, Martin D., Franks, Kevin N., Gilbert, Alexandra, Hanna, Gerard G., Hannaway, Nicola, Harrow, Stephen, Haswell, Tom, Hiley, Crispin T., Hinsley, Samantha, Krebs, Matthew, Murden, Geraldine, Phillip, Rachel, Ryan, Anderson J., Salem, Ahmed, Sebag-Montefoire, David, Shaw, Paul, Twelves, Chris J., Walker, Katrina, Young, Robin J., Faivre-Finn, Corinne, Greystoke, Alastair
• Format: Article
• Language: English
• Subjects: Continual reassessment method; DNA damage repair inhibitor; Non-small cell lung cancer; Platform trial; Sequential chemoradiotherapy
• ISSN: 2405-6308; 2405-6308
• DOI: 10.1016/j.ctro.2020.09.006

•Lung cancer is the leading cause of cancer mortality worldwide.•Gold standard chemoradiotherapy is not deliverable for the majority of patients.•Radiation-induced DNA damage repair is an actionable mechanism of radioresistance.•Careful trial design is essential to elicit maximum impact on therapeutic index.•CONCORDE is a platform study of novel drug/radiotherapy combinations in lung cancer. Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.